Complementary medicines: Emerging therapies for intestinal mucositis
نویسندگان
چکیده
منابع مشابه
Emerging Drug Therapies for Heart Failure
Heart failure is associated with high morbidity and mortality and is proving to be an economic burden in developing countries. A number of therapeutic agents are presently employed in heart failure; but they are not sufficient to control symptoms of heart failure. Moreover, the prevalence of chronic heart failure is progressively increasing and thus there is a continuing need to develop effecti...
متن کاملEmerging Therapies for Atherosclerosis
In the United States alone, about 250,000 people develop significant mitral regurgitation (MR) each year, with almost 50,000 undergoing surgery. Surgical repair of a diseased mitral valve has become the treatment of choice for patients with significant MR. Since there is no single therapeutic approach for every etiology of MR, surgical mitral valve repair includes a variety of techniques that a...
متن کاملEmerging Therapies for Osteoporosis
Although several effective therapies are available for the treatment of osteoporosis in postmenopausal women and older men, there remains a need for the development of even more effective and acceptable drugs. Several new drugs that are in late-stage clinical development will be discussed. Abaloparatide (recombinant parathyroid hormone related peptide [PTHrP] analogue) has anabolic activity lik...
متن کاملOral Mucositis Induced By Anticancer Therapies
Oral mucositis induced by conventional cytotoxic cancer therapies is a common and significant clinical problem in oncology. Mucositis symptoms, which include severe pain, may lead to dose reductions and unplanned interruptions of chemotherapy and/or radiotherapy, and often affect patients' quality of life. In addition, ulcerative mucositis represents a risk factor for local or systemic infectio...
متن کاملEmerging therapies.
The results of the European Cooperative Acute Stroke Study III (ECASS III) provide an important advance for the field of acute stroke therapy. The study was well-designed and conducted. The trial provides unequivocal and straightforward evidence that treatment with intravenous (IV) tissue plasminogen activator (tPA) initiated 3 to 4.5 hours after the onset of ischemic stroke improves 90-day out...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cancer Biology & Therapy
سال: 2009
ISSN: 1538-4047,1555-8576
DOI: 10.4161/cbt.8.17.9452